menu
    • menu

    Company profile for Pulmocide

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Pulmocide is a unique biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients’ quality of life. Unlike currently available treatments for fungal infections in the lung, our innovative approach to drug development provides targeted delivery to the lung so that infections can be treated with minimal unwant...
    Pulmocide is a unique biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients’ quality of life. Unlike currently available treatments for fungal infections in the lung, our innovative approach to drug development provides targeted delivery to the lung so that infections can be treated with minimal unwanted systemic effects.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Pulmocideunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    44 Southampton Buildings London WC2A 1AP
    Telephone
    Telephone
    +44 203 763 9484
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://pulmocide.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Product Expo West

    Natural Product Expo West

    Not Confirmed

    envelop Contact Supplier

    Natural Product Expo West

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pulmocide Ends OPERA-T Phase 3 Opelconazole Trial
    Pulmocide Ends OPERA-T Phase 3 Opelconazole Trial

    07 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/07/3214562/0/en/Pulmocide-Announces-Termination-of-Opera-T-Phase-3-Study-with-Opelconazole.html

    GLOBENEWSWIRE
    07 Jan 2026
    Share Share
    Pulmocide Announces Presentation at JP Morgan Healthcare Conference
    Pulmocide Announces Presentation at JP Morgan Healthcare Conference

    10 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/10/3007635/0/en/Pulmocide-Announces-Presentation-at-43rd-Annual-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    10 Jan 2025
    Share Share
    Pulmocide OPERA-S Inhaled Opelconazole Phase 2 Positive Results
    Pulmocide OPERA-S Inhaled Opelconazole Phase 2 Positive Results

    15 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/15/2862691/0/en/Pulmocide-Announces-Successful-Results-from-the-OPERA-S-Study-a-Phase-2-Safety-Study-with-Inhaled-Opelconazole.html

    GLOBENEWSWIRE
    15 Apr 2024
    Share Share
    Pulmocide exits OPERA with evidence of antifungal efficacy
    Pulmocide exits OPERA with evidence of antifungal efficacy

    15 Apr 2024

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/pulmocide-exits-opera-phase-2-evidence-antifungal-safety-and-efficacy

    Nick Paul Taylor FIERCE BIOTECH
    15 Apr 2024
    Share Share
    Pulmocide Announces Data Confirming Low Potential for Inhaled Opelconazole
    Pulmocide Announces Data Confirming Low Potential for Inhaled Opelconazole

    16 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/16/2760577/0/en/Pulmocide-Announces-New-Clinical-Data-Confirming-Low-Potential-for-Drug-Drug-Interactions-with-Inhaled-Opelconazole.html

    GLOBENEWSWIRE
    16 Oct 2023
    Share Share
    Pulmocide Announces Expansion of Management Team
    Pulmocide Announces Expansion of Management Team

    08 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/08/2684591/0/en/Pulmocide-Announces-Expansion-of-Management-Team.html

    GLOBENEWSWIRE
    08 Jun 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search